Hypertensive disorders of pregnancy in intensive care
https://orcid.org/0009-0004-4435-0528
Hypertensive disorders of pregnancy are one of the main causes of maternal mortality, especially in their most severe forms of presentation. This constitutes a serious public health problem, especially in developing countries as a result of the low use of prenatal care and obstetric care services, as well as the multidisciplinary approach and late admission to Intensive Care Units for comprehensive management. The objective of this review is: To present the best available medical evidence of comprehensive management for the diagnosis and treatment of hypertensive disorders of pregnancy in intensive care and thus reduce maternal and perinatal morbidity and mortality. Methodology: This theoretical descriptive documentary review was based on the search, selection and analysis of scientific articles in the Medline, Scielo, Scopus and BVS databases, related to hypertensive diseases of pregnancy. Articles with 10 years of publication were selected, and the MeSH search terms used were: Hypertension, pregnancy, preeclampsia, eclampsia, encephalopathy. 44 articles were preselected and 25 of them were included regarding the topic. Results: Updated information about hypertensive disorders of pregnancy in intensive care was obtained through the review of 44 selected articles, of which 25 were included for analysis based on inclusion and exclusion criteria, which allowed achieving the proposed objective. Conclusions: This work is a summarized version of the recommendations and evidence for the care of hypertensive complications in pregnancy in intensive care, which is expected to be adopted by health professionals in charge of pregnancy care in the country and thus reduce morbidity and mortality associated with pregnancy. It also becomes evident that it is necessary to create subspecialties in critical obstetrics.
ACOG. (2020, Junio). Gestational Hypertension and preeclampsia: ACOG Practice Bulletin Summary, number 22. Obstet Gynecol, 135(6), e237-e260.
Agrawal, S., Cerdeira, A., Redman, C., & Vatish, M. (2018). Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension, 71(2), 306-316.
Brown, M., Magee, L., & Kenny, L. (2018, Julio). Hypertensive disorder of pregnancy:ISSHP Classification,Diagnosis, and Management Recommendations for International Practice. Hypertension, 72(1), 24-43.
Butwick, A., Druzin, M., & Shaw, G. (2020). Evaluation of US State-level variation in Hypertensive disorder of pregnancy. JAMA Netw Open, 3(10), 1-12.
ESC Committee for practice Guidelines . (2018). ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur heart J.
INEC. (2021). Defunciones Generales . INEC.
Lisonkova, S., & Joseph, K. (2013). Incidence of preeclampsia:risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol, 209(6), 544.e1-544e12.
Macdonald-Wallis, C., Lawlor, D., & Heron, J. (2011). Relationships of risk factors for preeclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. PLoS One, 6(7), e221115.
Magee, L., Nicolaides, K., & von Dadelszen. (2022). Preeclampsia. N Engl J Med, 386(19), 1817-1832.
Magee, L., Pels, A., & Helewa, M. (2014). Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J obstet Gynaecol Can, 36, 416.
Malha, L., Sison, C., & Helseth, G. (2018). Renin-Angiotesin-Aldosterone profiles in pregnant women with Chronic hypertension. Hypertension, 72(2), 417-424.
Maynard, S., & Karumanchi, S. (2011, Enero). Angiogenic factors and preeclampsia. Semin Nephrol, 31(1), 33-46.
MSP. (2016). Guia Practica Clinica MSP. MSP.
NICE. (2019, June). Hypertension in prenancy: diagnosis and management. NICE guideline.
OMS. (2019). Mortalidad Materna. OMS.
Payne , B., Magee, L., & von Dadelszen, P. (2011). Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol, 25, 449.
Reddy, M., Rolnik, D., & Harris, K. (2020). Challenging the definition of hypertension in pregnancy: a retrospective cohort study. Am J Obstet Gynecol, 222, 6060.e1.
Roberts, J., Rich-Edwards, J., & McElrath, T. (2021). Subtypes of preeclampsia:recognition and determining clinical usefulness. Hipertension, 77, 1430-1441.
Shen, M., Smith, G., Rodger, M., White, R., Walker, M., & Wen, S. (2017). Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One, 12(4), e0175914.
Sinkey, R., Battarbee, A., Bello, N., Ives, C., Oparil, S., & Tita, A. (2020, Aug 27). Prevention, Diagnosis and management of Hypertensive disorders of pregnancy: A comparison of international Guidelines. Curr Hypertens Rep, 22(9), 66.
Sisti, G., & Colombi, I. (2019). New blood pressure cut off for preeclampsia definition:130/80mmHg. Eur J Obstet Gynecol reprod Biol, 240, 322-324.
Sutton, E., Rogan, S., & Lopa , S. (2020). Early Pregnancy Blood Pressure elevations and risk for maternal and morbidity. Obstet Gynecol, 136, 129.
Tranquilli, A., Dekker, G., & Magge, L. (2014). The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens, 4, 97.
UNICEF. (2020, Octubre 08). Mortalidad fetal durante el embarazo. UNICEF.
Verlohren, S., Stepan, H., & Dechend, R. (2012). Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond), 122(2), 43-52.
Williams, B., Mancia, G., & Spiering, W. (2019). Guia ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión. Esp Cardiol, 72(2), 1-78.
Wu, D., Gao, L., & Huang, O. (2020). Increased Adverse Pregnancy outcomes associated with stage 1 hypertension in a low-risk cohort:Evidense from 47874 cases. Hypertension, 75, 772.